FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3102157658> ?p ?o ?g. }

• W3102157658 endingPage "348" @default.
• W3102157658 startingPage "339" @default.
• W3102157658 abstract "Objectives To evaluate efficacy and safety of abatacept in adults with active primary Sjögren’s syndrome (pSS) in a phase III, randomised, double-blind, placebo-controlled trial. Methods Eligible patients (moderate-to-severe pSS [2016 ACR/European League Against Rheumatism (EULAR) criteria], EULAR Sjögren’s Syndrome Disease Activity Index [ESSDAI] ≥5, anti-SS-related antigen A/anti-Ro antibody positive) received weekly subcutaneous abatacept 125 mg or placebo for 169 days followed by an open-label extension to day 365. Primary endpoint was mean change from baseline in ESSDAI at day 169. Key secondary endpoints were mean change from baseline in EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) and stimulated whole salivary flow (SWSF) at day 169. Other secondary clinical endpoints included glandular functions and patient-reported outcomes. Selected biomarkers and immune cell phenotypes were examined. Safety was monitored. Results Of 187 patients randomised, 168 completed double-blind period and 165 continued into open-label period. Mean (SD) baseline ESSDAI and ESSPRI total scores were 9.4 (4.3) and 6.5 (2.0), respectively. Statistical significance was not reached for primary (ESSDAI −3.2 abatacept vs −3.7 placebo, p=0.442) or key secondary endpoints (ESSPRI, p=0.337; SWSF, p=0.584). No clinical benefit of abatacept over placebo at day 169 was seen with other clinical and PRO endpoints. Relative to baseline, abatacept was associated with significant differences vs placebo in some disease-relevant biomarkers (including IgG, IgA, IgM-rheumatoid factor) and pathogenic cell subpopulations (post hoc analyses). No new safety signals were identified. Conclusions Abatacept treatment did not result in significant clinical efficacy compared with placebo in patients with moderate-to-severe pSS, despite evidence of biological activity." @default.
• W3102157658 created "2020-11-23" @default.
• W3102157658 creator A5013156684 @default.
• W3102157658 creator A5018878859 @default.
• W3102157658 creator A5022458571 @default.
• W3102157658 creator A5023848798 @default.
• W3102157658 creator A5037814320 @default.
• W3102157658 creator A5052026761 @default.
• W3102157658 creator A5057619326 @default.
• W3102157658 creator A5061319680 @default.
• W3102157658 creator A5061683904 @default.
• W3102157658 creator A5065705574 @default.
• W3102157658 creator A5069264280 @default.
• W3102157658 creator A5083314956 @default.
• W3102157658 date "2020-11-09" @default.
• W3102157658 modified "2023-10-18" @default.
• W3102157658 title "Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial" @default.
• W3102157658 cites W1534996769 @default.
• W3102157658 cites W1790195495 @default.
• W3102157658 cites W1925295969 @default.
• W3102157658 cites W1969801895 @default.
• W3102157658 cites W1991852843 @default.
• W3102157658 cites W1994649501 @default.
• W3102157658 cites W2000969329 @default.
• W3102157658 cites W2002011103 @default.
• W3102157658 cites W2028514817 @default.
• W3102157658 cites W2044723511 @default.
• W3102157658 cites W2059189040 @default.
• W3102157658 cites W2072785268 @default.
• W3102157658 cites W2073704950 @default.
• W3102157658 cites W2078360998 @default.
• W3102157658 cites W2084563360 @default.
• W3102157658 cites W2085412199 @default.
• W3102157658 cites W2101453675 @default.
• W3102157658 cites W2104369521 @default.
• W3102157658 cites W2105452082 @default.
• W3102157658 cites W2111955466 @default.
• W3102157658 cites W2113102627 @default.
• W3102157658 cites W2114850377 @default.
• W3102157658 cites W2124670599 @default.
• W3102157658 cites W2134085268 @default.
• W3102157658 cites W2151541207 @default.
• W3102157658 cites W2176156606 @default.
• W3102157658 cites W2208460261 @default.
• W3102157658 cites W2340320857 @default.
• W3102157658 cites W2500435921 @default.
• W3102157658 cites W2502616982 @default.
• W3102157658 cites W2529618366 @default.
• W3102157658 cites W2540091234 @default.
• W3102157658 cites W2560381583 @default.
• W3102157658 cites W2592697450 @default.
• W3102157658 cites W2604923520 @default.
• W3102157658 cites W2617447744 @default.
• W3102157658 cites W2735166411 @default.
• W3102157658 cites W2753954593 @default.
• W3102157658 cites W2754704394 @default.
• W3102157658 cites W2777347920 @default.
• W3102157658 cites W2911841701 @default.
• W3102157658 cites W2954204270 @default.
• W3102157658 cites W2967761335 @default.
• W3102157658 cites W2982538063 @default.
• W3102157658 cites W3003307088 @default.
• W3102157658 cites W3013945520 @default.
• W3102157658 cites W4292528167 @default.
• W3102157658 doi "https://doi.org/10.1136/annrheumdis-2020-218599" @default.
• W3102157658 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7892395" @default.
• W3102157658 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33168545" @default.
• W3102157658 hasPublicationYear "2020" @default.
• W3102157658 type Work @default.
• W3102157658 sameAs 3102157658 @default.
• W3102157658 citedByCount "56" @default.
• W3102157658 countsByYear W31021576582020 @default.
• W3102157658 countsByYear W31021576582021 @default.
• W3102157658 countsByYear W31021576582022 @default.
• W3102157658 countsByYear W31021576582023 @default.
• W3102157658 crossrefType "journal-article" @default.
• W3102157658 hasAuthorship W3102157658A5013156684 @default.
• W3102157658 hasAuthorship W3102157658A5018878859 @default.
• W3102157658 hasAuthorship W3102157658A5022458571 @default.
• W3102157658 hasAuthorship W3102157658A5023848798 @default.
• W3102157658 hasAuthorship W3102157658A5037814320 @default.
• W3102157658 hasAuthorship W3102157658A5052026761 @default.
• W3102157658 hasAuthorship W3102157658A5057619326 @default.
• W3102157658 hasAuthorship W3102157658A5061319680 @default.
• W3102157658 hasAuthorship W3102157658A5061683904 @default.
• W3102157658 hasAuthorship W3102157658A5065705574 @default.
• W3102157658 hasAuthorship W3102157658A5069264280 @default.
• W3102157658 hasAuthorship W3102157658A5083314956 @default.
• W3102157658 hasBestOaLocation W31021576581 @default.
• W3102157658 hasConcept C126322002 @default.
• W3102157658 hasConcept C142724271 @default.
• W3102157658 hasConcept C203014093 @default.
• W3102157658 hasConcept C203092338 @default.
• W3102157658 hasConcept C204787440 @default.
• W3102157658 hasConcept C27081682 @default.
• W3102157658 hasConcept C2777489490 @default.
• W3102157658 hasConcept C2777575956 @default.
• W3102157658 hasConcept C2779338263 @default.

• next